ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Catalent extends in gene therapy, signs with Exelixis on ADCs

by Rick Mullin
September 11, 2020 | APPEARED IN VOLUME 98, ISSUE 35

 

Catalent says it will spend $130 million to add five manufacturing suites to its gene therapy facility in Harmans, Maryland. The pharmaceutical services firm is in the midst of a project to add 10 gene therapy suites, each with multiple bioreactors, by next year. The new project will be in an adjacent building and is expected on line by the first half of 2022. Separately, Catalent has formed a partnership with Exelixis to develop multiple antibody-drug conjugates (ADCs) in the drug company’s preclinical pipeline. Exelixis will pay Catalent $10 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment